1. Dionigi E, Garcovich M, Borzio M, Leandro G, Majumdar A, Tsami A, et al. Bacterial Infections Change Natural History of Cirrhosis Irrespective of Liver Disease Severity. The American journal of gastroenterology. 2017;112(4):588-96. doi: 10.1038/ajg.2017.19.
2. Fernández J, Acevedo J, Wiest R, Gustot T, Amoros A, Deulofeu C, et al. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. Gut. 2018;67(10):1870-80. doi: 10.1136/gutjnl-2017-314240.
3. Nahon P, Lescat M, Layese R, Bourcier V, Talmat N, Allam S, et al. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort). Gut. 2017;66(2):330-41. doi: 10.1136/gutjnl-2015-310275.
4. Piano S, Singh V, Caraceni P, Maiwall R, Alessandria C, Fernandez J, et al. Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology. 2019;156(5):1368-80.e10. doi: 10.1053/j.gastro.2018.12.005.
5. Macesic N, Gomez-Simmonds A, Sullivan SB, Giddins MJ, Ferguson SA, Korakavi G, et al. Genomic Surveillance Reveals Diversity of Multidrug-Resistant Organism Colonization and Infection: A Prospective Cohort Study in Liver Transplant Recipients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018;67(6):905-12. doi: 10.1093/cid/ciy199.
6. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. Journal of hepatology. 2014;60(6):1310-24. doi: 10.1016/j.jhep.2014.01.024.
7. Magiorakos AP, Burns K, Rodríguez Baño J, Borg M, Daikos G, Dumpis U, et al. Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. Antimicrob Resist Infect Control. 2017;6:113. doi: 10.1186/s13756-017-0259-z.
8. CHINET: https://www.chinets.com/Document/Index. Accessed 11 February 2022.
9. Gorrie CL, Mirceta M, Wick RR, Edwards DJ, Thomson NR, Strugnell RA, et al. Gastrointestinal Carriage Is a Major Reservoir of Klebsiella pneumoniae Infection in Intensive Care Patients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017;65(2):208-15. doi: 10.1093/cid/cix270.
10. Dickstein Y, Edelman R, Dror T, Hussein K, Bar-Lavie Y, Paul M. Carbapenem-resistant Enterobacteriaceae colonization and infection in critically ill patients: a retrospective matched cohort comparison with non-carriers. J Hosp Infect. 2016;94(1):54-9. doi: 10.1016/j.jhin.2016.05.018.
11. Lin Q, Wang Y, Yu J, Li S, Zhang Y, Wang H, et al. Bacterial characteristics of carbapenem-resistant Enterobacteriaceae (CRE) colonized strains and their correlation with subsequent infection. BMC infectious diseases. 2021;21(1):638. doi: 10.1186/s12879-021-06315-0.
12. Institute CaLS. Performance Standards for Antimicrobial Susceptibility Testing.CLSI M100 ED31:2021. Wayne: Clincal and Laboratory Standards Institute. 2021.
13. Testing TECoAS: http://www.eucast.org. Accessed 1 January 2021.
14. Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int. 2014;8(4):453-71. doi: 10.1007/s12072-014-9580-2.
15. Chen HY, Jean SS, Lee YL, Lu MC, Ko WC, Liu PY, et al. Carbapenem-Resistant Enterobacterales in Long-Term Care Facilities: A Global and Narrative Review. Front Cell Infect Microbiol. 2021;11:601968. doi: 10.3389/fcimb.2021.601968.
16. Lin MY, Lyles-Banks RD, Lolans K, Hines DW, Spear JB, Petrak R, et al. The importance of long-term acute care hospitals in the regional epidemiology of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013;57(9):1246-52. doi: 10.1093/cid/cit500.
17. Lee CM, Lai CC, Chiang HT, Lu MC, Wang LF, Tsai TL, et al. Presence of multidrug-resistant organisms in the residents and environments of long-term care facilities in Taiwan. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2017;50(2):133-44. doi: 10.1016/j.jmii.2016.12.001.
18. Chen H, Au KM, Hsu KE, Lai CK, Myint J, Mak YF, et al. Multidrug-resistant organism carriage among residents from residential care homes for the elderly in Hong Kong: a prevalence survey with stratified cluster sampling. Hong Kong medical journal = Xianggang yi xue za zhi. 2018;24(4):350-60. doi: 10.12809/hkmj176949.
19. Le MN, Kayama S, Yoshikawa M, Hara T, Kashiyama S, Hisatsune J, et al. Oral colonisation by antimicrobial-resistant Gram-negative bacteria among long-term care facility residents: prevalence, risk factors, and molecular epidemiology. Antimicrob Resist Infect Control. 2020;9(1):45. doi: 10.1186/s13756-020-0705-1.
20. McKinnell JA, Singh RD, Miller LG, Kleinman K, Gussin G, He J, et al. The SHIELD Orange County Project: Multidrug-resistant Organism Prevalence in 21 Nursing Homes and Long-term Acute Care Facilities in Southern California. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019;69(9):1566-73. doi: 10.1093/cid/ciz119.
21. Mao YC, Chang CL, Huang YC, Su LH, Lee CT. Laboratory investigation of a suspected outbreak caused by Providencia stuartii with intermediate resistance to imipenem at a long-term care facility. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2018;51(2):214-9. doi: 10.1016/j.jmii.2016.07.004.
22. Yan L, Sun J, Xu X, Huang S. Epidemiology and risk factors of rectal colonization of carbapenemase-producing Enterobacteriaceae among high-risk patients from ICU and HSCT wards in a university hospital. Antimicrob Resist Infect Control. 2020;9(1):155. doi: 10.1186/s13756-020-00816-4.
23. Rai S, Das D, Niranjan DK, Singh NP, Kaur IR. Carriage prevalence of carbapenem-resistant Enterobacteriaceae in stool samples: A surveillance study. The Australasian medical journal. 2014;7(2):64-7. doi: 10.4066/amj.2014.1926.
24. Pan F, Tian D, Wang B, Zhao W, Qin H, Zhang T, et al. Fecal carriage and molecular epidemiology of carbapenem-resistant Enterobacteriaceae from outpatient children in Shanghai. BMC infectious diseases. 2019;19(1):678. doi: 10.1186/s12879-019-4298-3.
25. Tang HJ, Hsieh CF, Chang PC, Chen JJ, Lin YH, Lai CC, et al. Clinical Significance of Community- and Healthcare-Acquired Carbapenem-Resistant Enterobacteriaceae Isolates. PloS one. 2016;11(3):e0151897. doi: 10.1371/journal.pone.0151897.
26. Chiotos K, Tamma PD, Flett KB, Naumann M, Karandikar MV, Bilker WB, et al. Multicenter Study of the Risk Factors for Colonization or Infection with Carbapenem-Resistant Enterobacteriaceae in Children. Antimicrob Agents Chemother. 2017;61(12). doi: 10.1128/aac.01440-17.
27. Goodman KE, Simner PJ, Klein EY, Kazmi AQ, Gadala A, Rock C, et al. How frequently are hospitalized patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) already on contact precautions for other indications? Infect Control Hosp Epidemiol. 2018;39(12):1491-3. doi: 10.1017/ice.2018.236.
28. Prasad N, Labaze G, Kopacz J, Chwa S, Platis D, Pan CX, et al. Asymptomatic rectal colonization with carbapenem-resistant Enterobacteriaceae and Clostridium difficile among residents of a long-term care facility in New York City. Am J Infect Control. 2016;44(5):525-32. doi: 10.1016/j.ajic.2015.11.021.
29. Madueño A, González García J, Ramos MJ, Pedroso Y, Díaz Z, Oteo J, et al. Risk factors associated with carbapenemase-producing Klebsiella pneumoniae fecal carriage: A case-control study in a Spanish tertiary care hospital. Am J Infect Control. 2017;45(1):77-9. doi: 10.1016/j.ajic.2016.06.024.
30. Freire MP, Oshiro IC, Pierrotti LC, Bonazzi PR, de Oliveira LM, Song AT, et al. Carbapenem-Resistant Enterobacteriaceae Acquired Before Liver Transplantation: Impact on Recipient Outcomes. Transplantation. 2017;101(4):811-20. doi: 10.1097/tp.0000000000001620.
31. Pereira MR, Scully BF, Pouch SM, Uhlemann AC, Goudie S, Emond JE, et al. Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2015;21(12):1511-9. doi: 10.1002/lt.24207.
32. Phichaphop C, Apiwattanakul N, Techasaensiri C, Lertudomphonwanit C, Treepongkaruna S, Thirapattaraphan C, et al. High prevalence of multidrug-resistant gram-negative bacterial infection following pediatric liver transplantation. Medicine (Baltimore). 2020;99(45):e23169. doi: 10.1097/md.0000000000023169.
33. Zhong L, Men T-Y, Li H, Peng Z-H, Gu Y, Ding X, et al. Multidrug-resistant gram-negative bacterial infections after liver transplantation – Spectrum and risk factors. Journal of Infection. 2012;64(3):299-310. doi: https://doi.org/10.1016/j.jinf.2011.12.005.
34. Zhang W, Wang W, Kang M, Wu S, Liu Y, Liao Q, et al. Bacterial and Fungal Infections After Liver Transplantation: Microbial Epidemiology, Risk Factors for Infection and Death with Infection. Annals of transplantation. 2020;25:e921591. doi: 10.12659/aot.921591.
35. Cheruvattath R, Balan V. Infections in Patients With End-stage Liver Disease. Journal of clinical gastroenterology. 2007;41(4):403-11. doi: 10.1097/01.mcg.0000248018.08515.f9.
36. Iovleva A, Doi Y. Carbapenem-Resistant Enterobacteriaceae. Clinics in laboratory medicine. 2017;37(2):303-15. doi: 10.1016/j.cll.2017.01.005.
37. Cui X, Zhang H, Du H. Carbapenemases in Enterobacteriaceae: Detection and Antimicrobial Therapy. Frontiers in microbiology. 2019;10:1823. doi: 10.3389/fmicb.2019.01823.
38. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends in molecular medicine. 2012;18(5):263-72. doi: 10.1016/j.molmed.2012.03.003.
39. Han R, Shi Q, Wu S, Yin D, Peng M, Dong D, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China. Front Cell Infect Microbiol. 2020;10:314. doi: 10.3389/fcimb.2020.00314.
40. Wang Q, Wang X, Wang J, Ouyang P, Jin C, Wang R, et al. Phenotypic and Genotypic Characterization of Carbapenem-resistant Enterobacteriaceae: Data From a Longitudinal Large-scale CRE Study in China (2012-2016). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018;67(suppl_2):S196-s205. doi: 10.1093/cid/ciy660.
41. Huang W, Zhang J, Zeng L, Yang C, Yin L, Wang J, et al. Carbapenemase Production and Epidemiological Characteristics of Carbapenem-Resistant Klebsiella pneumoniae in Western Chongqing, China. Front Cell Infect Microbiol. 2021;11:775740. doi: 10.3389/fcimb.2021.775740.
42. Khan MA, Mohamed AM, Faiz A, Ahmad J. Enterobacterial infection in Saudi Arabia: First record of Klebsiella pneumoniae with triple carbapenemase genes resistance. Journal of infection in developing countries. 2019;13(4):334-41. doi: 10.3855/jidc.11056.
43. Vannice K, Benoliel E, Kauber K, Brostrom-Smith C, Montgomery P, Kay M, et al. Notes from the Field: Clinical Klebsiella pneumoniae Isolate with Three Carbapenem Resistance Genes Associated with Urology Procedures - King County, Washington, 2018. MMWR Morbidity and mortality weekly report. 2019;68(30):667-8. doi: 10.15585/mmwr.mm6830a4.
44. Yang P, Chen Y, Jiang S, Shen P, Lu X, Xiao Y. Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014. Antimicrob Resist Infect Control. 2018;7:137. doi: 10.1186/s13756-018-0430-1.
45. Zeng L, Yang C, Zhang J, Hu K, Zou J, Li J, et al. An Outbreak of Carbapenem-Resistant Klebsiella pneumoniae in an Intensive Care Unit of a Major Teaching Hospital in Chongqing, China. Front Cell Infect Microbiol. 2021;11:656070. doi: 10.3389/fcimb.2021.656070.
46. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clinical microbiology reviews. 2005;18(2):306-25. doi: 10.1128/cmr.18.2.306-325.2005.
47. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;52(3):1028-33. doi: 10.1128/aac.01020-07.
48. Nadasy KA, Domiati-Saad R, Tribble MA. Invasive Klebsiella pneumoniae syndrome in North America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007;45(3):e25-8. doi: 10.1086/519424.
49. Wang H, Min C, Li J, Yu T, Hu Y, Dou Q, et al. Characterization of fosfomycin resistance and molecular epidemiology among carbapenem-resistant Klebsiella pneumoniae strains from two tertiary hospitals in China. BMC microbiology. 2021;21(1):109. doi: 10.1186/s12866-021-02165-7.
50. Perez F, El Chakhtoura NG, Papp-Wallace KM, Wilson BM, Bonomo RA. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy? Expert opinion on pharmacotherapy. 2016;17(6):761-81. doi: 10.1517/14656566.2016.1145658.
51. Jin L, Wang R, Wang X, Wang Q, Zhang Y, Yin Y, et al. Emergence of mcr-1 and carbapenemase genes in hospital sewage water in Beijing, China. J Antimicrob Chemother. 2018;73(1):84-7. doi: 10.1093/jac/dkx355.
52. Poirel L, Jayol A, Bontron S, Villegas MV, Ozdamar M, Türkoglu S, et al. The mgrB gene as a key target for acquired resistance to colistin in Klebsiella pneumoniae. J Antimicrob Chemother. 2015;70(1):75-80. doi: 10.1093/jac/dku323.
53. Cannatelli A, D'Andrea MM, Giani T, Di Pilato V, Arena F, Ambretti S, et al. In vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. Antimicrob Agents Chemother. 2013;57(11):5521-6. doi: 10.1128/aac.01480-13.
54. Wright MS, Suzuki Y, Jones MB, Marshall SH, Rudin SD, van Duin D, et al. Genomic and transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal multiple pathways of resistance. Antimicrob Agents Chemother. 2015;59(1):536-43. doi: 10.1128/aac.04037-14.
55. Bassetti M, Eckmann C, Bodmann KF, Dupont H, Heizmann WR, Montravers P, et al. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. J Antimicrob Chemother. 2013;68 Suppl 2:ii5-14. doi: 10.1093/jac/dkt140.
56. Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, et al. Carbapenemase-Producing Organisms: A Global Scourge. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018;66(8):1290-7. doi: 10.1093/cid/cix893.
57. Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, et al. Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;63(12):1615-8. doi: 10.1093/cid/ciw636.
58. Spellberg B, Bonomo RA. Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: "We're Gonna Need a Bigger Boat". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;63(12):1619-21. doi: 10.1093/cid/ciw639.
59. Lan P, Jiang Y, Zhou J, Yu Y. A global perspective on the convergence of hypervirulence and carbapenem resistance in Klebsiella pneumoniae. Journal of global antimicrobial resistance. 2021;25:26-34. doi: 10.1016/j.jgar.2021.02.020.
60. Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nature Reviews Microbiology. 2020;18(6):344-59. doi: 10.1038/s41579-019-0315-1.
61. David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, et al. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nature microbiology. 2019;4(11):1919-29. doi: 10.1038/s41564-019-0492-8.
62. Meng X, Yang J, Duan J, Liu S, Huang X, Wen X, et al. Assessing Molecular Epidemiology of Carbapenem-resistant Klebsiella pneumoniae (CR-KP) with MLST and MALDI-TOF in Central China. Scientific reports. 2019;9(1):2271. doi: 10.1038/s41598-018-38295-8.
63. Li JJ, Sheng ZK, Deng M, Bi S, Hu FS, Miao HF, et al. Epidemic of Klebsiella pneumoniae ST11 clone coproducing KPC-2 and 16S rRNA methylase RmtB in a Chinese University Hospital. BMC infectious diseases. 2012;12:373. doi: 10.1186/1471-2334-12-373.
64. Paul D, Babenko D, Toleman MA. Human carriage of cefotaxime-resistant Escherichia coli in North-East India: an analysis of STs and associated resistance mechanisms. J Antimicrob Chemother. 2020;75(1):72-6. doi: 10.1093/jac/dkz416.
65. Yoo JS, Kim HM, Koo HS, Yang JW, Yoo JI, Kim HS, et al. Nosocomial transmission of NDM-1-producing Escherichia coli ST101 in a Korean hospital. Journal of Antimicrobial Chemotherapy. 2013;68(9):2170-2. doi: 10.1093/jac/dkt126.
66. Solgi H, Giske CG, Badmasti F, Aghamohammad S, Havaei SA, Sabeti S, et al. Emergence of carbapenem resistant Escherichia coli isolates producing bla(NDM) and bla(OXA-48)-like carried on IncA/C and IncL/M plasmids at two Iranian university hospitals. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2017;55:318-23. doi: 10.1016/j.meegid.2017.10.003.
67. Gamal D, Fernández-Martínez M, El-Defrawy I, Ocampo-Sosa AA, Martínez-Martínez L. First identification of NDM-5 associated with OXA-181 in Escherichia coli from Egypt. Emerging microbes & infections. 2016;5(4):e30. doi: 10.1038/emi.2016.24.
68. Qin S, Fu Y, Zhang Q, Qi H, Wen JG, Xu H, et al. High incidence and endemic spread of NDM-1-positive Enterobacteriaceae in Henan Province, China. Antimicrob Agents Chemother. 2014;58(8):4275-82. doi: 10.1128/aac.02813-13.